Theravance Biopharma Inc (0TB) — Net Asset Quality Index
Theravance Biopharma Inc (0TB) has a Net Asset Quality Index of 56.0% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of €415.46 Million minus total liabilities of €182.78 Million yields net assets of €232.68 Million. A higher index indicates a stronger, lower-leverage balance sheet. Check how resilient are Theravance Biopharma Inc's assets to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Theravance Biopharma Inc Net Asset Quality Index Over Time (2014–2024)
This chart shows how Theravance Biopharma Inc's Net Asset Quality Index has evolved across 11 annual periods from 2014 to 2024. As of September 2025, the index stands at 56.0%, representing net assets of €232.68 Million against total assets of €415.46 Million EUR. See Theravance Biopharma Inc (0TB) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Theravance Biopharma Inc (2014–2024)
The table below presents the year-by-year Net Asset Quality Index for Theravance Biopharma Inc from 2014 to 2024, covering 11 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Theravance Biopharma Inc (0TB) total market value.
| Year | Quality Index | Net Assets (EUR) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 49.6% | €175.54 Million | €354.16 Million | €178.62 Million | ▼ -6.2 pp |
| 2023 | 55.8% | €213.00 Million | €382.00 Million | €169.00 Million | ▼ -17.0 pp |
| 2022 | 72.7% | €441.80 Million | €607.40 Million | €165.60 Million | ▲ +163.1 pp |
| 2021 | -90.3% | €-338.57 Million | €374.82 Million | €713.39 Million | ▼ -25.6 pp |
| 2020 | -64.8% | €-303.75 Million | €469.06 Million | €772.81 Million | ▼ -10.0 pp |
| 2019 | -54.8% | €-223.84 Million | €408.83 Million | €632.67 Million | ▼ -45.5 pp |
| 2018 | -9.2% | €-51.59 Million | €560.24 Million | €611.82 Million | ▼ -35.3 pp |
| 2017 | 26.1% | €115.18 Million | €441.40 Million | €326.22 Million | ▼ -28.7 pp |
| 2016 | 54.8% | €350.23 Million | €639.25 Million | €289.02 Million | ▼ -26.2 pp |
| 2015 | 81.0% | €243.06 Million | €300.12 Million | €57.05 Million | ▼ -4.8 pp |
| 2014 | 85.8% | €289.79 Million | €337.77 Million | €47.98 Million | — |